Skip to content
TrialScanner

NCT05572684

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

Phase 1/Phase 2TerminatedNXTCLeadMRKCollaborator

Registry record

Lead sponsor
NextCure, Inc.
Conditions
Advanced or Metastatic Solid Tumors; Microsatellite Instability Low; Microsatellite Instability High; Microsatellite Stable; Ovarian Cancer
Primary completion
Apr 30, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05572684 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.